Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal avastin and macugen versus intravitreal mono-therapy - A pilot study

Current Eye Research

Volumn 36, Issue 10, 2011, Pages 958-963

  Schmid Kubista, Katharina E ^a   Krebs, Ilse ^a   Ansari Shahrezaei, Siamak ^a   Haas, Paulina ^a   Hagen, Stefan ^a   Binder, Susanne ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Intravitreal injection; Pegaptanib

Indexed keywords

BEVACIZUMAB; PEGAPTANIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTRAST SENSITIVITY; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; RETREATMENT; THICKNESS; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CONTRAST SENSITIVITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80053324684     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.597536     Document Type: Article

References (22)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
2. Ferris FL, 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642. (Pubitemid 15204559)
3. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870. (Pubitemid 44547437)
4. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology. 2009;116:S1-7.
5. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: A report by the American Academy of Ophthalmology. Ophthalmology. 2008;115:1837-1846.
6. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351:2805-2816. (Pubitemid 40051904)
7. Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev. 2006;5:123-132.
8. Chakravarthy U, Adamis AP, Cunningham ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508 e1-25.
9. Friberg TR, Tolentino M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol. 2010;94:1611-1617.
10. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
11. Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S. Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study. Br J Ophthalmol. 2009;93:914-919.
12. Radner W, Obermayer W, Richter-Mueksch S, Willinger U, Velikay-Parel M, Eisenwort B. The validity and reliability of short German sentences for measuring reading speed. Graef Arch Clin Exp. 2002;240:461-467. (Pubitemid 36097067)
13. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin).Retina. 2006;26:257-261. (Pubitemid 44318176)
14. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthal Surg Las Im. 2005;36:331-335. (Pubitemid 41073112)
15. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372.
16. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina. 2006;26:383-390. (Pubitemid 44197628)
17. Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol. 2008;92:356-360. (Pubitemid 351363530)
18. Tufail A. Bevacizumab for neovascular age related macular degeneration (ABC Trial): Multicenter randomised double masked study. Br J Ophthalmol. 2010;340:2459.
19. Keane PA, Patel PJ, Ouyang Y, et al. Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. Invest Ophth Vis Sci. 2010;51:5431-5437.
20. Joeres S, Kaplowitz K, Brubaker JW, et al. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Ophthalmology. 2008;115:347-354.
21. Hudson PJ, Souriau C. Engineered antibodies. Nat Med. 2003;9:129-134. (Pubitemid 36098274)
22. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao- Reis F, Soares R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009;88:522-527.